Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims regarding St. John’s wort and its effect on atorvastatin are not supported by the provided FDA label excerpts. Some statin safety/muscle and liver monitoring statements are supported, but the response heavily relies on unsupported St. John’s wort interaction assertions.
Category Scores
Accurate Statements
Statins can rarely cause serious muscle problems.
Supported in provided label: 5.1 (rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria).
Muscle aches or weakness (mild to severe) can occur with atorvastatin (Lipitor).
Supported in provided label: 5.1 (myopathy defined as muscle aches or muscle weakness in conjunction with CPK >10x ULN).
Severe muscle pain, tenderness, or weakness (especially with feeling unwell) can be a sign of possible statin-related muscle injury.
Supported in provided label: 5.1 and 17.1 (advice to report unexplained muscle pain/tenderness/weakness, particularly if accompanied by malaise or fever; myopathy considerations).
Yellowing of the skin or eyes (jaundice) can indicate possible liver problems with atorvastatin.
Supported in provided label: 5.2 (one patient developed jaundice).
Unsupported Statements
St. John’s wort can speed up the breakdown of many drugs in the liver through enzyme induction.
St. John’s wort is not mentioned anywhere in the provided label excerpts; no enzyme-induction claim is supported.
Combining atorvastatin (Lipitor) and St. John’s wort can change how much Lipitor stays in the system.
No St. John’s wort-atovastatin interaction or pharmacokinetic effect is provided in the label excerpts.
Changing how much Lipitor stays in the system may increase the chance of side effects related to poor drug control.
The label supports increased myopathy risk with certain interacting drugs, but does not link this to St. John’s wort or altered atorvastatin levels from St. John’s wort.
Changing how much Lipitor stays in the system may also affect overall tolerability.
No label support in provided excerpts for tolerability impacts specifically tied to St. John’s wort or St. John’s wort-altered atorvastatin exposure.
Nausea, constipation, or diarrhea can occur with atorvastatin (Lipitor).
The provided label excerpts do not include GI adverse reactions.
Headache can occur with atorvastatin (Lipitor).
The provided label excerpts do not include headache adverse reactions.
Dark or tea-colored urine can be a sign of possible statin-related muscle injury.
No urine discoloration symptom guidance is present in the provided label excerpts.
Severe or persistent upper belly pain can indicate possible liver problems.
No upper abdominal pain symptom guidance appears in the provided label excerpts.
Unusual bruising or bleeding can indicate possible liver problems.
No bruising/bleeding symptom guidance appears in the provided label excerpts.
Severe fatigue can indicate possible liver problems.
No fatigue symptom guidance appears in the provided label excerpts.
St. John’s wort can lower levels of some medications by increasing drug metabolism.
St. John’s wort is not discussed in the provided label excerpts; no metabolism-lowering mechanism is supported.
Lowering atorvastatin exposure may reduce cholesterol lowering effectiveness.
The provided label excerpts do not state that reduced atorvastatin exposure reduces cholesterol-lowering effectiveness (and do not discuss St. John’s wort).
Reduced cholesterol lowering effectiveness can matter for long-term cardiovascular risk.
The provided label excerpts discuss cholesterol/cardiovascular risk factors, but do not connect reduced atorvastatin effectiveness (from St. John’s wort or reduced exposure) to long-term risk.
St. John’s wort is known for interactions with many drugs.
No St. John’s wort interaction statement exists in the provided label excerpts.
Clinicians often avoid St. John’s wort in people taking prescription medicines because of drug interactions.
No such clinical practice statement appears in the provided label excerpts.
The risk is that multiple drugs can be affected, not only Lipitor.
Because St. John’s wort is not addressed in the provided label excerpts, the St. John’s wort–specific multi-drug effect statement is not supported.
If using St. John’s wort, medications and supplements should be reviewed with a pharmacist or clinician.
The label excerpts advise discussing/conveying all medications with healthcare professionals generally, but do not mention St. John’s wort specifically.
Contradictions
Important Omissions
For the St. John’s wort-related claims, the label excerpts provide no St. John’s wort dosing/management guidance; the response implies specific interaction effects without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported St. John’s wort interaction claims could mislead patients/clinicians about specific risks or effects involving atorvastatin; some muscle/liver warning elements are supported by the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple St. John’s wort–specific claims are not supported by the provided FDA label excerpts, including effects on atorvastatin exposure, metabolism, and cholesterol-lowering effectiveness.
Suggested Improvement
Remove or rewrite St. John’s wort interaction claims to reflect only supported atorvastatin interaction information present in the provided label excerpts (e.g., increased myopathy risk with specific interacting agents listed in 5.1/7) and include only label-supported symptom guidance for myopathy and liver dysfunction.